Notre Faculté

Oliver Freudenreich, M.D.

Oliver Freudenreich, M.D.

Co-director of the MGH Psychosis Clinical and Research Program, Massachusetts General Hospital
Professor of Clinical Psychiatry, Harvard Medical School

Biographie

Dr. Oliver Freudenreich, M.D., FACLP, is a professor of psychiatry at Harvard Medical School and a psychiatrist at Massachusetts General Hospital (MGH), serves as co-director of the MGH Psychosis Clinical and Research Program, and directs the MGH Fellowship in Public and Community Psychiatry. His academic interest lies in the area of optimal psychopharmacological treatment for schizophrenia, including the development of innovative treatments and management of treatment-resistant psychosis.

Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness and for diagnostically difficult cases with psychosis. He also serves on local and national committees related to disaster preparedness. He has published extensively in his areas of interest and has written a handbook on psychotic disorders; its second edition was published in 2020. He teaches and speaks on a regular basis at international and national meetings.

His recent awards include the MGH Department of Psychiatry Clinical Excellence Award and the 2022 Outstanding Psychiatrist Award for the Public Sector from the Massachusetts Psychiatric Society.

Publications de Oliver Freudenreich, M.D.

[FR] Quick Take Vol. 83

0.75 CMEs
When should you consider high-dose olanzapine instead of clozapine for treatment-resistant schizophrenia? How effective is aripiprazole augmentation versus switching strategies in older adults with depression? Can GLP-1 receptor agonists elevate lithium levels? Should inflammatory markers guide antidepressant selection? Is adjunctive propranolol effective for panic disorder?
Faculté: James Phelps, M.D., Paul Zarkowski, M.D., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D.
38.56 minutes en 0 sections audio

[FR] Quick Take Vol. 81

0.50 CMEs
Can ondansetron improve negative symptoms in schizophrenia? Will lithium orotate prevent or reverse Alzheimer's disease? What predicts treatment response in bipolar disorder? Should we increase SSRI doses or try alternative strategies for inadequate response? Is trazodone safe for treating insomnia in alcohol use disorder?
Faculté: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Paul Zarkowski, M.D., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D.
36.33 minutes en 5 sections audio

[FR] Quick Take Vol. 80

0.75 CMEs
How effective is the new antipsychotic KarXT using the number needed to treat metric? Can bright light therapy effectively treat bipolar depression without causing mania? Does IV haloperidol really increase cardiac risks as commonly believed? Can varenicline help reduce alcohol intake in people with alcohol use disorder? Does ashwagandha extract improve cognitive function in mild cognitive impairment?
Faculté: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D., Derick E. Vergne, M.D.
39.35 minutes en 5 sections audio

[FR] Quick Take Vol. 79

0.75 CMEs
How should clozapine monitoring change after FDA's REMS removal? Does cariprazine work equally well in older adults with bipolar disorder? Can semaglutide help treat alcohol use disorder? Why do older adults receive subtherapeutic antidepressant doses? Is saffron as effective as SSRIs for depression?
Faculté: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Kristin Raj, M.D., Derick E. Vergne, M.D.
44.22 minutes en 0 sections audio

À la découverte de notre bibliothèque de plus de 440 à des conférences vidéo, des podcasts, des résumés de travaux de recherche et des interviews d'experts.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.